| 瑞舒伐他汀对2型糖尿病视网膜病变患者血清PEDF、IL-6水平的影响 |
| 投稿时间：2014-07-03 修订日期：2014-08-26 点此下载全文 |
| 引用本文：彭湾湾,曾姣娥.瑞舒伐他汀对2型糖尿病视网膜病变患者血清PEDF、IL-6水平的影响[J].医学研究杂志,2015,44(2):150-153 |
| DOI：
10.3969/j.issn.1673-548X.2015.02.042 |
| 摘要点击次数: 1073 |
| 全文下载次数: 959 |
|
|
| 中文摘要:目的 探讨瑞舒伐他汀对2型糖尿病视网膜病变(DR)患者血清PEDF、IL-6水平的影响。方法 选取60例2型糖尿病视网膜病变患者, 随机分为实验组(瑞舒伐他汀治疗)30例和空白对照组(仅常规降血糖治疗)30例, 疗程为3个月。分析两组患者治疗前后血清PEDF、IL-6、TC、TG、LDL、HDL、FPG、2hPG、HbA1c水平以及DR分期的变化情况。结果 实验组血清IL-6、TC、TG、LDL、FPG、2hPG、HbA1c水平及DR分期与治疗前比较明显下降, 血清PEDF、HDL水平与治疗前比较明显升高, 差异均有统计学意义(P<0.01)。空白对照组中FPG、2hPG、HbA1c水平较治疗前明显下降(P<0.01), 其余各指标与治疗前比较, 差异均无统计学意义(P > 0.05)。实验组治疗前后的差值(ΔPEDF、ΔIL-6、ΔDR分期、ΔTC、ΔTG、ΔLDL、ΔHDL)与对照组治疗前后的差值比较, 差异均有统计学意义(P<0.01)。结论 瑞舒伐他汀能显著降低DR患者血清IL-6水平, 升高血清PEDF水平, 从而延缓了DR患者的病情进展。 |
| 中文关键词:瑞舒伐他汀 2型糖尿病视网膜病变 色素上皮衍生因子 白介素-6 |
| |
| Influence of Rosuvastatin on Serum Pigment Epithelium Derived-factor,Interleukin-6 in Patients with Type 2 Diabetic Retinopathy |
|
|
| Abstract:Objective To observe the effect of rosuvastatin on serum pigment epithelium derived-factor(PEDF), interleukin-6(IL-6) in patients with type2 diabetic retinopathy(DR). Methods We selected 60 pitients with type 2 diabetic retinopathy who were randomly divided into two groups after three-months long treatments of rosuvastatin(30cases) and blank(30cases, Only hypoglycemic therapy). Patients before and after treatment were observed for serum PEDF, IL-6, Total cholesterol(TC), Triglyceride(TG), Low density lipoprotein(LDL), High density lipoprotein (HDL), Fasting plasma glucose (FPG), 2-hour postprandial glucose(2hPG), Glycosylated hemoglobin(HbA1c) and the stages of diabetic retinopathy changes. Results In the experimental group after three-months long treatments of rosuvastatin, the content of serum IL-6, TC, TG, LDL, FPG, 2hPG, HbA1c and the stages of diabetic retinopathy were decreased significantly compared to the previous(P<0.01), and the content of serum PEDF、HDL were increased significantly compared to the previous(P<0.01).The blank control group were not given rosuvastatin therapy.After three-months, the content of FPG, 2hPG, HbA1c were decreased significantly compared to the previous(P<0.01), other indicators did not alter significantly, and the difference were not statistically significant(P > 0.05).The difference between the experimental group before and after treatment(ΔPEDF, ΔIL-6, ΔDR, ΔTC, ΔTG, ΔLDL, ΔHDL)compared to the blank control group were statistically significant(P<0.01). Conclusion Rosuvastatin can reduce the concentration of serum IL-6, increase the concentration of serum PEDF, thus delay the progression of diabetic retinopathy. |
| keywords:Rosuvastatin Type 2 diabetic retinopathy Pigment epithelium derived-factor Interleukin-6 |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
